Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445019 | 0.81 | — | — | |
| SCHEMBL853114 | 0.77 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL7334888 | 0.74 | — | — | |
| SCHEMBL21049142 | 0.74 | — | — | |
| SCHEMBL14604846 | 0.74 | — | — | |
| SCHEMBL14268324 | 0.74 | — | — | |
| SCHEMBL7337865 | 0.74 | — | — | |
| SCHEMBL18389141 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12293155 | 0.71 | — | — | |
| SCHEMBL9444949 | 0.71 | ALDH1A1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303845-B1 | Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8524737-B2 | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-20110190340-A1 | BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190340-A1 | BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | RHOT2, MYLK2, ROCK2 | ALDH1A1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.